Suppr超能文献

免疫检查点抑制剂诱导的 1 型糖尿病中的人类白细胞抗原和生物标志物。

Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors.

机构信息

Department of Diabetes and Endocrinology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

The First Department of Medicine, Wakayama Medical University, Wakayama, Japan.

出版信息

Endocrinol Metab (Seoul). 2022 Feb;37(1):84-95. doi: 10.3803/EnM.2021.1282. Epub 2022 Feb 28.

Abstract

BACKGROUND

Type 1 diabetes mellitus induced by immune-checkpoint inhibitors (ICI-T1DM) is a rare critical entity. However, the etiology of ICI-T1DM remains unclear.

METHODS

In order to elucidate risk factors for ICI-T1DM, we evaluated the clinical course and immunological status of patients with ICI-T1DM who had been diagnosed during 2016 to 2021.

RESULTS

Seven of 871 (0.8%, six men and one woman) patients developed ICI-T1DM. We revealed that the allele frequencies of human leukocyte antigen (HLA)-DPA102:02 and DPB105:01 were significantly higher in the patients with ICI-T1DM In comparison to the controls who received ICI (11/14 vs. 10/26, P=0.022; 11/14 vs. 7/26, P=0.0027, respectively). HLA-DRB104:05, which has been found to be a T1DM susceptibility allele in Asians, was also observed as a high-risk allele for ICI-T1DM. The significance of the HLA-DPB105:01 and DRB1*04:05 alleles was confirmed by an analysis of four additional patients. The absolute/relative neutrophil count, neutrophils-lymphocyte ratio, and neutrophil-eosinophil ratio increased, and the absolute lymphocyte count and absolute/relative eosinophil count decreased at the onset as compared with 6 weeks before. In two patients, alterations in cytokines and chemokines were found at the onset.

CONCLUSION

Novel high-risk HLA alleles and haplotypes were identified in ICI-T1DM, and peripheral blood factors may be utilized as biomarkers.

摘要

背景

免疫检查点抑制剂(ICI)引起的 1 型糖尿病(ICI-T1DM)是一种罕见的危急病症。然而,ICI-T1DM 的病因仍不清楚。

方法

为了阐明 ICI-T1DM 的危险因素,我们评估了 2016 年至 2021 年期间诊断出的 ICI-T1DM 患者的临床过程和免疫状态。

结果

871 例患者中有 7 例(0.8%,6 名男性和 1 名女性)发生 ICI-T1DM。我们发现,与接受 ICI 的对照组相比(11/14 比 10/26,P=0.022;11/14 比 7/26,P=0.0027),ICI-T1DM 患者的人类白细胞抗原(HLA)-DPA102:02 和 DPB105:01 等位基因频率显著更高。在亚洲人中已被发现为 1 型糖尿病易感等位基因的 HLA-DRB104:05 也被观察为 ICI-T1DM 的高危等位基因。另外 4 名患者的分析证实了 HLA-DPB105:01 和 DRB1*04:05 等位基因的意义。与发病前 6 周相比,发病时绝对/相对中性粒细胞计数、中性粒细胞-淋巴细胞比值和中性粒细胞-嗜酸性粒细胞比值增加,而绝对淋巴细胞计数和绝对/相对嗜酸性粒细胞计数减少。在两名患者中,发病时发现细胞因子和趋化因子的改变。

结论

在 ICI-T1DM 中发现了新的高危 HLA 等位基因和单倍型,外周血因子可用作生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de2/8901959/75cfca56a4dc/enm-2021-1282f1.jpg

相似文献

1
Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors.
Endocrinol Metab (Seoul). 2022 Feb;37(1):84-95. doi: 10.3803/EnM.2021.1282. Epub 2022 Feb 28.
8
Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice.
Diabetes Metab J. 2023 Nov;47(6):757-766. doi: 10.4093/dmj.2023.0072. Epub 2023 Jul 24.
9
Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.
Diabetes Care. 2022 May 1;45(5):1170-1176. doi: 10.2337/dc21-2213.
10
HLA DRB1, DQB1 and insulin promoter VNTR polymorphisms: interactions and the association with adult-onset diabetes mellitus in Czech patients.
Int J Immunogenet. 2008 Apr;35(2):133-40. doi: 10.1111/j.1744-313X.2008.00749.x. Epub 2008 Feb 11.

引用本文的文献

2
Durvalumab-induced Type 1 Diabetes in a Patient With Pre-existing GADA-positive Diabetes and Preserved Insulin Secretion.
JCEM Case Rep. 2025 Jan 24;3(2):luae252. doi: 10.1210/jcemcr/luae252. eCollection 2025 Feb.
5
Immune checkpoint inhibitor-related type 1 diabetes incidence, risk, and survival association.
J Diabetes Investig. 2025 Feb;16(2):334-342. doi: 10.1111/jdi.14362. Epub 2024 Nov 21.
8
Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors.
Cancers (Basel). 2024 Mar 20;16(6):1225. doi: 10.3390/cancers16061225.
10
Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab.
Diabetol Int. 2023 Aug 28;15(1):130-134. doi: 10.1007/s13340-023-00659-5. eCollection 2024 Jan.

本文引用的文献

3
Genetics of fulminant type 1 diabetes.
Diabetol Int. 2020 Sep 21;11(4):315-322. doi: 10.1007/s13340-020-00468-0. eCollection 2020 Oct.
4
Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors.
Endocr J. 2021 Feb 28;68(2):231-241. doi: 10.1507/endocrj.EJ20-0371. Epub 2020 Oct 3.
7
Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients.
Clin Transl Oncol. 2021 Feb;23(2):311-317. doi: 10.1007/s12094-020-02420-9. Epub 2020 Jun 19.
8
Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets.
Clin Transl Immunology. 2020 Mar 16;9(3):e1122. doi: 10.1002/cti2.1122. eCollection 2020.
9
Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Cancer Sci. 2020 May;111(5):1468-1477. doi: 10.1111/cas.14363. Epub 2020 Mar 17.
10
Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
Front Endocrinol (Lausanne). 2020 Jan 28;11:14. doi: 10.3389/fendo.2020.00014. eCollection 2020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验